Stelara 130 MG/26 ML vial 26ML
Ended Awarded
- Contract number
- SPE2DB26FDD88
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,787
Award facts
- Contract value 100% obligated
- $3,787.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,787.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 130 mg/26 mL vials. The delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated as SPE2DR, which was established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative on November 13, 2025.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to supply a comprehensive range of pharmaceutical products, biologics, and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's IDC ceiling value of $499,999,999 with a completion date of December 31, 2036, comprises a 30-month base period and three 30-month option periods, positioning the company as a critical pharmaceutical supplier for military healthcare operations. The contractor's extensive product portfolio and demonstrated performance across numerous delivery orders for specialized pharmaceuticals including immunosuppressants, biologics, and specialty medications underscore its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FDD88?
SPE2DB26FDD88 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 30, 2025.
How much is contract SPE2DB26FDD88 worth?
The government has obligated $3,787 on SPE2DB26FDD88.
Is contract SPE2DB26FDD88 an order under another contract?
Yes. SPE2DB26FDD88 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD88 competed?
The extent of competition for SPE2DB26FDD88 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award